Why ChondroFiller is not available on the NHS

For most patients researching ChondroFiller, the first practical question is whether the NHS can fund it. The straightforward answer is no — and the reason is structural rather than a reflection on the treatment's clinical merit.

NHS commissioning in England follows a defined route: a therapy must first undergo a health technology appraisal (HTA) by the National Institute for Health and Care Excellence (NICE), which evaluates clinical evidence and cost-effectiveness before recommending whether the NHS should fund it. ChondroFiller has not entered that process. Without a completed NICE appraisal, no commissioning framework exists for it, which means a GP cannot write a referral that any NHS pathway is equipped to accept — the infrastructure to receive and process that referral simply does not exist.

The only cartilage cell therapy that has completed this route is Autologous Chondrocyte Implantation (ACI), which received NICE approval under Technology Appraisal TA477 in October 2017 and is available at a small number of specialist surgical centres, including the Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH). ACI is a surgical procedure involving harvest and reimplantation of the patient's own chondrocytes under general anaesthetic. ChondroFiller is mechanistically and procedurally entirely different — an acellular injectable collagen scaffold placed in an outpatient setting — and falls completely outside TA477's approval scope.

Some patients consider whether an Individual Funding Request (IFR) to their NHS trust might be a viable workaround. There is currently no established precedent of an IFR being approved for ChondroFiller, so this is not a realistic route to pursue. Private self-funding is, at present, the only available access pathway.

What ChondroFiller is and how it works

Seconds after ChondroFiller enters the joint space, something chemically precise happens: the liquid collagen formulation encounters the joint's neutral pH environment and begins to self-polymerise, forming a dimensionally stable hydrogel scaffold within approximately three to five minutes. No heat, no external activation, and no surgical manipulation are required — the gelation is triggered by the joint's own chemistry.

The resulting scaffold is not a passive filler. Through a process called acellular matrix-induced chondrogenesis, it signals the body's own progenitor cells — drawn from the surrounding synovium and subchondral bone — to migrate into the defect site and begin producing repair tissue. The scaffold itself gradually resorbs as that repair process matures, leaving behind endogenously generated tissue rather than a permanent implant. This distinguishes ChondroFiller clearly from long-duration hydrogel products designed to remain in the joint indefinitely.

The product is manufactured by Meidrix Biomedicals GmbH in Germany and is imported into the UK under prescription. Its regulatory status is CE-marked Class III — the highest-risk device category, which reflects the product's active biological role inside the joint rather than any concern about safety in the conventional sense. Class III classification indicates that the device interacts directly with the body's repair processes in a way that demands the most rigorous pre-market scrutiny.

In the current service pathway at London Cartilage Clinic, ChondroFiller is placed under real-time ultrasound guidance as an outpatient appointment — no incision, no general anaesthetic, and no theatre admission.

Patients most likely to benefit

The typical patient arriving for a ChondroFiller assessment carries a specific kind of history: a focal cartilage lesion — usually confirmed on MRI — that has continued to cause localised pain, swelling, or mechanical symptoms such as catching or giving way despite a reasonable course of physiotherapy.

In clinical grading terms, the core indication is Grade III or IV articular cartilage damage on the ICRS or Outerbridge scale. In plain language, this describes cartilage that has thinned substantially or worn down to expose the bone beneath — damage significant enough that the body's routine repair processes cannot address it unaided. Grade I or II changes, where cartilage remains largely intact, are generally outside the indication.

Two factors that do not rule anyone out at this stage are age and defect size. The injection pathway carries no upper age limit and no cap on lesion dimensions; these variables are assessed at consultation rather than used as blanket filters.

The more nuanced question concerns diffuse osteoarthritis without a clearly defined focal component, which sits outside the core indication. However, patients who have both broader joint change and an identifiable focal lesion on MRI are not automatically disqualified — provided the focal component can be confirmed on imaging, wider background joint change alone is not a hard exclusion. What the MRI needs to show is a discrete, addressable defect; whether it does is determined at the formal imaging review during consultation.

How to access ChondroFiller privately in London

Accessing ChondroFiller privately requires no GP referral. Patients self-refer directly — a meaningful distinction from the standard NHS pathway, where specialist access depends on a primary care letter. Anyone considering treatment can move at their own pace and timeline.

The practical route runs through four stages:

Discover. The starting point is either a free discovery call or a short online suitability assessment available through the clinic website. Both take only a few minutes and exist specifically to establish whether a formal consultation is the appropriate next step for a patient's situation.

Assess. The formal assessment is an approximately one-hour consultation during which existing MRI and imaging is reviewed and a treatment plan agreed. This is the appointment where the focal defect — and any broader joint context — is matched against the individual's clinical picture.

Consult and treat. Once a plan is in place, the image-guided injection appointment follows. As covered above, this is an outpatient procedure; patients leave the clinic the same day.

For those travelling from outside London, London Cartilage Clinic at 66 Harley Street can coordinate the consultation, imaging review, and injection into a single focused visit — a practical option for international patients.

The clinic was the first in the UK to offer ChondroFiller through this injection pathway rather than as a surgically implanted device. It is led by Professor Paul Y. F. Lee, whose ICRS Teaching Centre of Excellence accreditation reflects the specialist oversight that appropriate use of a CE-marked Class III device requires.

Costs and what the price covers

The guide cost for a single-box treatment at London Cartilage Clinic is £3,000 — and because most focal cartilage defects require only one injection, this is the entry point that applies to the majority of patients. Two boxes are priced at £5,500; three at £8,000. Every tier is fully inclusive: consultation, ultrasound guidance, the ChondroFiller product itself, IV antibiotic cover during the procedure, and a six-week follow-up appointment. There are no itemised extras to account for separately.

The number of boxes used depends on defect size and joint location, confirmed once imaging has been reviewed at consultation — at which point your treating clinician will confirm the exact cost before any commitment is made.

Combination pathways for more complex presentations

For patients whose imaging shows significant background joint change alongside a focal defect, two escalated protocols are available. The first pairs ChondroFiller with Arthrosamid (a permanent polyacrylamide hydrogel) at a guide cost of £6,000. The two products work through distinct mechanisms: ChondroFiller is an acellular regenerative scaffold that recruits the body's own progenitor cells to promote endogenous repair, while Arthrosamid acts as a long-lasting hydrogel cushion within the synovial lining to modulate symptoms in more advanced Kellgren-Lawrence Grade III–IV osteoarthritis. The combination is not interchangeable with either agent alone.

The tri-active protocol — ChondroFiller, Arthrosamid, and MSC (Medicinal Signalling Cells) — is priced at £11,000 and is reserved for cases of more substantial joint involvement. For ongoing joint preservation, a longitudinal lifetime programme incorporates bi-annual ChondroFiller top-ups alongside annual imaging.

Private health insurance and getting started

Private health insurance may contribute to the cost, though not reliably. Bupa, Aviva, and WPA have each authorised ChondroFiller in individual cases — procedures are billed under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 — but these are case-specific decisions, not standing policy commitments. The same insurer may reach a different outcome for a different patient depending on policy wording, the clinical documentation submitted, and precisely how the procedure is coded.

Two practical rules follow. Written pre-authorisation must be in place before treatment starts; retroactive claims are unlikely to succeed. Partial cover is also a realistic outcome: some policies meet the professional fee while excluding the implant cost, or vice versa, and policy excesses can leave a significant share of the cost with the patient regardless. Knowing exactly what is and is not covered before booking removes an unwelcome financial surprise at the billing stage.

Patients who self-fund pay the all-inclusive guide costs confirmed at consultation, with no items billed separately afterwards.

The most useful preparation before a first appointment is to review your policy's exclusions list and pre-authorisation clause. A suitability consultation — available through londoncartilage.com — establishes the clinical case; the insurer's authorisation process can then run alongside, with the documentation from that assessment to hand.